Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71305/Aktiencheck_Vidac_120723.001.png
Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Erstkl. Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. 208% Biotech Hot Stock nach 31.205% mit Amgen

 

12.07.23 08:02

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

Accolade: A Rising Personalized AI-Powered Healthcare Platform: https://www.marketbeat.com/logos/articles/med_20230709131618_chart-accd.jpg
Accolade: A Rising Personalized AI-Powered Healthcare Platform

Accolade Inc. (NASDAQ: ACCD) is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people

3 Stocks that Analysts Continue to Upgrade into Earnings Season: https://www.marketbeat.com/logos/articles/med_20230710103919_3-stocks-that-analysts-continue-to-upgrade-into-ea.jpg
3 Stocks that Analysts Continue to Upgrade into Earnings Season

One simple signal that investors can use to decide if a stock is likely to move higher is to look at analyst sentiment. An analyst is a market professional employed by either funds that buy

Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi: https://www.marketbeat.com/logos/articles/med_20230707134150_biogen-shares-fall-after-fda-approval-of-alzheimer.jpg
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. (NASDAQ: BIIB) swooned 2.88% in heavy trading volume following news of full

Pfizer Just Invested $25 million In This Biotech: https://www.marketbeat.com/logos/articles/med_20230707085820_pfizer-just-invested-25-million-in-this-biotech.jpg
Pfizer Just Invested $25 million In This Biotech

Shares of Caribou Biosciences (NASDAQ: CRBU) were up 45% yesterday after Pfizer (NYSE: PFE) made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million

Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy: https://www.marketbeat.com/logos/articles/med_20230706072115_inspire-medical-up-15-after-breakout-analysts-say.jpg
Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy

Inspire Medical Systems (NYSE: INSP) is up nearly 15% since breaking out of cup-with-handle base on May 3. The base’s buy point was above $277.18, which you can see on the Inspire Medical Systems

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac : https://www.irw-press.at/prcom/images/messages/2023/71224/AC_VidacPharma_050723.001.png
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 134.452% mit Biogen

 

05.07.23 08:17

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71203/Acresearch040723_01.001.png
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 31.205% mit Amgen ($AMGN)

 

04.07.23

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Freyr Battery Powers Up After Successful Tests, NYSE Presentation: https://www.marketbeat.com/logos/articles/med_20230630155856_freyr-battery-powers-up-after-successful-tests-nys.png
Freyr Battery Powers Up After Successful Tests, NYSE Presentation

Investors dream of getting into a promising stock early before it goes on a rocket ride. In hindsight, plenty of investors are kicking themselves for not seeing the potential of Apple Inc.

Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?: https://www.marketbeat.com/logos/articles/med_20230628085658_down-over-80-is-pet-insurer-trupanion-worth-the-ri.jpg
Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?

As shareholders of pet insurer Trupanion Inc. (NASDAQ: TRUP) learned last month, when you post a net loss that's twice what Wall Street expected, things get a little fuzzy.

The May 5

MoonLake Immunotherapeutics Makes a Moonshot on Trials: https://www.marketbeat.com/logos/articles/med_20230627135359_chart-mltx.jpg
MoonLake Immunotherapeutics Makes a Moonshot on Trials

Clinical stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies

Drugmaker GSK: Becoming a Healthier Value Stock: https://www.marketbeat.com/logos/articles/med_20230627104026_drugmaker-gsk-is-becoming-a-healthier-value-stock.jpg
Drugmaker GSK: Becoming a Healthier Value Stock

Like most stocks during the dot-com bubble, GSK PLC (NYSE: GSK) partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceuti

PetVivo Sales Spryng Higher on Injectable OA Relief for Pets: https://www.marketbeat.com/logos/articles/med_20230625124449_chart-petv.jpg
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets

Developmental biomedical device company PetVivo Holdings Inc. (OTCMKTS: PETV) makes pet medical devices and therapeutics. What kind of medical devices would pets need? Pacemakers? Artificial hearts

Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?): https://www.marketbeat.com/logos/articles/med_20230627075714_sarepta-therapeutics-gets-fda-nod-drops-warning-or.jpg
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)

On May 15, Sarepta Therapeutics Inc. (NASDAQ: SRPT) learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA)

ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials: https://www.marketbeat.com/logos/articles/med_20230625130240_chart-imgn2.jpg
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials

ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver

Patterson Companies Leverages Healthcare For Income Investors: https://www.marketbeat.com/logos/articles/med_20230621111455_chart-pdco-6212023.png
Patterson Companies Leverages Healthcare For Income Investors

Patterson Companies, Inc. (NASDAQ: PDCO) is a dual-story that includes healthcare for humans and animals. The company operates in 2 segments, Dental and Animal Health, and both are growing. The

T-Mobile Stock's Decline: Does Value Potential Exist?: https://www.marketbeat.com/logos/articles/med_20230621142449_t-mobile-stocks-decline-does-value-potential-exist.jpg
T-Mobile Stock's Decline: Does Value Potential Exist?

Investors rarely get to consider a blue-chip company like T-Mobile US (NASDAQ: TMUS) amid a decline of more than 17% during the past two months. As the underlying stock carries a beta of only

Agilent Technologies Stock: Ready to Rise off the Floor: https://www.marketbeat.com/logos/articles/med_20230618154044_chart-a.jpg
Agilent Technologies Stock: Ready to Rise off the Floor

Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down 19% year-to-date. Agilent is a leading global provider of laboratory technologies and equipment.

It counts

DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth: https://www.marketbeat.com/logos/articles/med_20230621092054_dexcom-clears-base-wall-street-eyes-double-digit-e.jpg
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth

You generally associate Super Bowl commercials with products made by PepsiCo Inc. (NYSE: PEP) or the Coca-Cola Co. (NYSE: KO), but earlier this year, glucose-monitoring geat maker DexCom Inc.